JP Morgan Chase’s SOPHiA GENETICS SOPH Stock Holding History

JP Morgan Chase’s Portfolio SOPH Stock Details SOPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Buy	+35,000	New	+$178K	﹤0.01%	5592

Other funds holding SOPH

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

ACM

AKRE Capital Management Middleburg, Virginia $5.12B AUM 19.08% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

JP Morgan Chase's SOPH Position: Q2 2026 in Review

JP Morgan Chase sold out of SOPHiA GENETICS (SOPH) in Q2 2026, closing a stake of 206 shares — an estimated $1.04K sold.

JP Morgan Chase first reported a position in SOPH in Q3 2021 and held it in 10 quarters. The position peaked at $272K in Q1 2023. 72 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

JP Morgan Chase reported no remaining SOPHiA GENETICS position as of Q2 2026 after selling out during the quarter.
JP Morgan Chase sold 206 SOPHiA GENETICS shares in Q2 2026, an estimated $1.04K.
JP Morgan Chase first reported a position in SOPHiA GENETICS in Q3 2021 and held it in 10 quarters.
JP Morgan Chase's SOPHiA GENETICS position peaked at $272K in Q1 2023.
72 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.